Clinical Scorecard: This Week’s Biopharma News: ADCs, Biosimilars, and Microbiome Moves
At a Glance
| Category | Detail |
|---|---|
| Condition | |
| Key Mechanisms | Antibody-drug conjugates, microbiome co-therapy, anti-CD47 monoclonal antibodies |
| Target Population | |
| Care Setting |
Key Highlights
- Sacituzumab tirumotecan met phase 3 endpoints in endometrial cancer.
- MB097 showed positive phase 1b results in advanced melanoma.
- Ligufalimab demonstrated a survival signal in phase 2 AML trial.
- Regeneron's LAG-3 combination failed to meet phase 3 melanoma endpoint.
- FDA approved first golimumab biosimilars.
Guideline-Based Recommendations
Diagnosis
- Evaluate patients for advanced or recurrent cancer.
Management
- Consider sacituzumab tirumotecan for endometrial cancer after prior therapies.
- Use MB097 in combination with pembrolizumab for melanoma patients with primary resistance.
Monitoring & Follow-up
- Monitor for adverse events in patients receiving microbiome therapy.
Risks
- Assess risks of elevated viscosity and aggregation in high-concentration monoclonal antibodies.
Patient & Prescribing Data
Patients with advanced or recurrent cancer, including those ineligible for intensive chemotherapy.
Combination therapies are being explored for improved outcomes in various cancers.
Clinical Best Practices
- Utilize pregnancy registries for postapproval safety studies.
- Integrate protein engineering and real-time analytics in high-concentration mAb manufacturing.
Related Resources & Content
- FDA Guidance on Pregnancy Safety Studies
- Merck TroFuse-005 Trial Data
- Microbiotica MELODY-1 Trial Results
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
